Jazz Pharmaceuticals plc

NASDAQ:JAZZ   10:31:02 AM EDT
134.59
-0.46 (-0.34%)
Products

U.S. FDA Grants Orphan Drug Exclusivity For Xywav® Oral Solution For Idiopathic Hypersomnia In Adults

Published: 01/03/2022 21:34 GMT
Jazz Pharmaceuticals plc (JAZZ) - U.S. FDA Grants Orphan Drug Exclusivity (ode) for Xywav® (calcium, Magnesium, Potassium, and Sodium Oxybates) Oral Solution for Idiopathic Hypersomnia in Adults.
Jazz Pharmaceuticals Plc - Ode for Ih for Adults Follows June 2021 Grant of Ode for Treatment of Cataplexy.